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Determining early surrogate markers of long-term graft
outcome is important for optimal medical management. In
order to identify such markers, we used clinical information
from a cross-validated French database (Donne´es
Informatise´es et VAlide´es en Transplantation) of 2169 kidney
transplant recipients to construct a composite score 1 year
after transplantation. This Kidney Transplant Failure Score
took into account a series of eight accepted pre- and post-
transplant risk factors of graft loss, and was subsequently
evaluated for its ability to predict graft failure at 8 years. This
algorithm outperformed the traditional surrogates of serum
creatinine and the estimated graft filtration rate, with an area
under the receiver–operator characteristic curve of 0.78.
Validation on an independent database of 317 graft
recipients had the same predictive capacity. Our algorithm
was also able to stratify patients into two groups according
to their risk: a high-risk group of 81 patients with 25% graft
failure and a low-risk group of 236 patients with an 8%
failure rate. Thus, although this clinical composite score
predicts long-term graft survival, it needs validation in
different patient groups throughout the world.
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For decades, the conventional end point to estimate the
efficacy of new drugs such as cyclosporine has been the 1-year
graft survival.1–3 However, the significant increase in graft
survival during the cyclosporine era4,5 led to the occurrence
of acute rejection episodes during the first post-transplant
year becoming a more popular end point of efficacy when
appreciating the effect of novel therapeutics such as the anti-
interleukin-2 receptor antibody,6 mycophenolate mofetil,7
and tacrolimus.8 Nevertheless, the dramatic decrease in the
incidence of acute rejection episodes over recent years has
forged the challenge to define new pertinent surrogate end
points to replace acute rejection or graft survival.9 More
recently, composite end points combining drug efficacy and
safety have been used.10 From a methodological standpoint,
the main advantage of mixing different types of failures is the
higher frequency of the end point. However, the definition of
such a composite variable is often arbitrary and varies from
one study to another. Protocol biopsies have also been
proposed as a useful short-term end point of long-term
outcome.11,12 Despite a low risk/benefit ratio, biopsies
remain a costly and invasive procedure.13
More recently, non-invasive (blood or urine) biomarkers
have been proposed for the prediction of rejection episodes,
such as perforin or granzyme B transcripts,14 or for the
prediction of long-term kidney graft outcome, such as blood
levels of soluble CD30 (ref. 15) or donor-specific antibodies.16
However, these biomarkers still need further validation in large
patient cohorts, and often seem too late to be useful as
surrogate markers. For example, the mean time to the
appearance of donor-specific antibodies is 15–20 months.17
Currently, the 6- and 12-month post-transplant serum
creatinine (Cr) level is considered to be the simplest marker
that is significantly correlated with graft survival.18–20
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However, although 6–12-month serum Cr level correlates
with graft loss, this marker has been shown to be poorly
predictive.21 Several other pre- and post-transplant clinical
covariates have also been associated with a reduced long-term
graft loss, such as donor and recipient age,22,23 HLA
incompatibilities,24,25 pre-transplant immunization,26 and
delayed graft function.27 New early and predictive composite
end points are thus needed for a more rapid evaluation of
protocols and for decision-making in the clinical manage-
ment of kidney graft recipients.28
In this study, we used a new strategy to characterize a
clinical composite score at 1 year, called the Kidney
Transplant Failure Score (KTFS). The KTFS takes into
account a series of well-accepted pre- and post-transplant
risk factors of graft loss. The score itself is calculated using
the traditional multivariate Cox model29 combined with a
new statistical approach called the ‘time-dependent recei-
ver–operator characteristic (ROC) curves’, making it possible
to assess the predictive capacity of the surrogate marker that
is being evaluated.30
RESULTS
Characteristics of the training and test sets
The characteristics of the population are shown in Tables 1
and 2. Among the 2169 training-set patients, the mean
follow-up time was 5.1 years (±2.7) and 380 patients still
had a functional renal transplant at 8 years. The other
recipients died (n¼ 72), returned to dialysis (n¼ 169), or
were censored (n¼ 1548). The censored patients were those
who had a functioning graft at their last follow-up, but their
follow-up was o8 years. In all, 82% of patients were
recipients of a first kidney transplant. The mean donor age
was 45.2 years (range 1–83), 63.3% were male and 31.7% died
of vascular brain damage. Male recipients accounted for
61.9% of the population. The mean Cr value was 139.1mmol/l
at 6 months and 131.9 mmol/l at 1 year of follow-up.
Certain demographic characteristics of the test population
differed from those of the training population. The
transplant recipients and donors in the test set were
significantly younger than those of the training set, and only
1.9% of patients were re-transplanted in the test set
compared with 18.1% in the training set (Po0.0001). In
addition, donor males were more frequent in the test set. This
selection may explain the differences also observed for the
parameters collected during the follow-up. For instance, the
1-year estimated graft filtration rate (eGFR) mean was
51.2ml/min in the training set versus 62.4ml/min in the
test set (Po0.0001). We also observed a higher percentage of
acute rejection episodes in the training set (P¼ 0.0072).
These differences endow our analysis with an advantage,
because they provide an opportunity to test the robustness of
the composite KTFS applied to different populations.
Description of the KTFS
Eight factors were retained after the multivariate analysis of
kidney graft survival. The KTFS, weighted on the corrected
log hazard ratios of the Cox model, is defined by the
following formula:
KTFS ¼0:75072  CrD  1:02316  AgeR
þ1:17295  Ntransþ 0:22288  AR
þ0:01881  Cr3m þ 0:41551
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðCr12mÞ
p
0:88001  Gender þ 0:61121  Pr12m
þ0:04077  ðPr12mÞ2þ0:48601  Gender  Pr12m
0:06115  Gender  ðPr12mÞ2:
The definitions of the factors are provided in Table 3 and
the complete Cox model is described in Table 4, with the
corrected weights. When the corrected weight is positive, the
KTFS increases with the value of this risk factor. For instance,
Table 1 | Demographic and clinical characteristics of quantitative factors (mean, interquartile interval)
Learning sample (n=2169) Testing sample (n=317) P-value
Recipient age (years) 48.0 (38.0; 58.0) 45.3 (35.0; 55.7) 0.0005
Body mass index (kg/m2) 23.6 (20.5; 26.0) 23.3 (20.5; 25.5) 0.3178
Delayed graft function (days) 6.4 (1.0; 10.0) 3.0 (1.0; 3.0) o0.0001
Cold ischemia time (h) 23.5 (16.7; 30.8) 22.7 (17.0; 28.0) 0.3800
HLA-incompatibilities 3.0 (2.0; 4.0) 3.0 (2.0; 4.0) 0.9278
Last donor Cr (mmol/l) 98.6 (67.0; 112.0) 102.5 (70.0; 113.0) 0.4236
Panel reactive antibody on T cells 9.7 (0.0; 0.0) 7.7 (0.0; 0.0) 0.1403
Donor age (years) 45.2 (34.0; 56.0) 38.9 (26.0; 49.0) o0.0001
3-month Cr (mmol/l) 142.4 (106.0; 165.0) 132.4 (105.0; 149.0) 0.0002
6-month Cr (mmol/l) 139.1 (106.0; 160.5) 131.9 (105.0; 144.0) 0.0183
1-year Cr (mmol/l) 139.8 (106.0; 160.0) 134.6 (106.0; 148.0) 0.1182
1-year eGFR (ml/min) 51.2 (38.9; 62.1) 62.4 (48.5; 73.8) o0.0001
3-month Pr (g/day) 0.4 (0.1; 0.4) 0.3 (0.0; 0.3) 0.0044
6-month Pr (g/day) 0.4 (0.1; 0.4) 0.3 (0.0; 0.3) 0.0008
1-year Pr (g/day) 0.4 (0.1; 0.4) 0.3 (0.0; 0.3) 0.5469
Abbreviations: Cr, creatinine; eGFR, estimated graft filtration rate; HLA, human leukocyte antigen; Pr, proteinuria.
The demographic and biological characteristics of the training set (n=2169, from the hospitals of Nantes, Paris Necker, Nancy, Toulouse, and Montpellier) and the test set
(n=317, from the transplantation centers of Caen, Grenoble, Tours, and Strasbourg). Only quantitative factors are included with the descriptions of means and interval inter-
quartiles. The significance of the differences between means was statistically evaluated using a t-test, except for the body mass index and the delayed graft function, for
which the P-values were obtained using a log-rank test.
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the KTFS increases with the number of previous transplanta-
tions (Ntrans) and with the blood Cr values at 3 and 12
months (Cr3m and Cr12m). On the contrary, if the corrected
weight is negative, the KTFS decreases with the value of each
risk factor. For example, the KTFS is lower for male recipients
compared with female recipients. More accurately, when the
KTFS increases by 0.7, the risk of graft failure increases by
twofold (Po0.0001). This increase is represented in Figure 1,
for which the score was categorized into 10 classes. The mean
KTFS was 4.00 (±1.34), and 50% of the patients had a KTFS
43.73 (range 1.23–15.33). This distribution is shown in
Figure 2.
Predictive properties of the KTFS in the training set
As explained in the methods section of the time-dependent
ROCmethodology, the correlation of the KTFS with the risk of
graft failure (Po0.0001) is not sufficient to demonstrate
its capacity to predict graft survival. Lachenbruch et al.16
also insisted on this distinction between ‘correlation’ and
‘prediction’. Thus, we next evaluated whether it could also
predict graft survival. The area under the ROC curve (AUC) of
the KTFS was 0.78 (confidence interval (CI)95%¼ (0.73, 0.80)),
indicating that the KTFS was a powerful predictor of graft
failure before the eighth anniversary. In comparison, the AUC
of the 1-year Cr was 0.73 (CI95%¼ (0.67, 0.76)), but this
predictive capacity was significantly lower than that of the
KTFS (Po0.0001, one-tailed test by bootstrap resampling).
The prognostic accuracy of the 1-year eGFR was equivalent to
that of Cr (AUC¼ 0.70, CI95%¼ (0.66, 0.75)). Finally, the DCr
(from 6 to 12 months) was even less powerful (AUC¼ 0.60,
CI95%¼ (0.58, 0.69)) than the KTFS (Po0.0001). The
corresponding ROC curves are presented in Figure 3a.
As the KTFS is a quantitative variable, it is important
to identify subgroups according to their risk of graft failure.
Table 2 | Demographic and clinical characteristics (qualitative
factors)
Training set (%)
(n=2169)
Test set (%)
(n=317) P-value
Male recipients 61.9 65.0 0.3101
Male donors 63.3 68.6 0.0820
First transplantation 81.9 98.1 o0.0001
Acute rejection episode 23.9 16.8 0.0072
The demographic and biological characteristics of the training set (n=2169, from the
hospitals of Nantes, Paris Necker, Nancy, Toulouse, and Montpellier) and the test set
(n=317, from the transplantation centers of Caen, Grenoble, Tours, and Strasbourg).
Only qualitative factors are included with the listing of percentages. The significance
of the differences between percentages was statistically evaluated using a w2-test.
Table 3 | Values for the risk factors included in the KTFS
calculation
Abbreviation Value
Gender 1 for male recipients and 0 for females
CrD 1 if the blood creatinine of the donor is 4190mmol/l,
and 0 otherwise
AgeR 1 if the recipient age is 425 years, and 0 otherwise
Ntrans 1 if the number of previous transplantations is 42,
and 0 otherwise
Cr3m Blood creatinine level measured 3-months
post-transplantation in mmol/dl
Cr12m Blood creatinine level measured 1-year
post-transplantation in mmol/l
Pr12m Proteinuria measured 1-year post-transplantation
in g/day
AR 1 if an acute rejection occurs in the first year,
and 0 otherwise
Abbreviation: KTFS, Kidney Transplant Failure Score; ROC, receiver-operator characteristic.
These definitions are chosen in order to maximize the quality of adjustment to the Cox
model and to maximize the area under the time-dependent ROC curve at 8 years. To
calculate the KTFS for a subject, the abbreviations in the KTFS formula (page 2) are simply
replaced by the corresponding value. If at least one variable is missing, the KTFS cannot
be calculated.
Table 4 | The multivariate Cox model from the training set
(n=2169) and the corresponding corrected weights (corrected
log HR) obtained by maximization of the area under the ROC
curve for a prognostic at 8 years
Variables HR log HR CI95% HR P-value
Corrected
weights
CrD 0.46 0.76811 (0.19; 1.13) 0.0920 0.75072
AgeR 0.37 0.99039 (0.23; 0.61) 0.0001 1.02316
Ntrans 2.94 1.07866 (1.68; 5.16) 0.0002 1.17295
AR 1.29 0.25468 (0.94; 1.77) 0.1100 0.22288
Cr3m 0.96 0.03844 (0.93; 0.99) 0.0098 0.01881ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðCr12mÞ
p
1.55 0.44031 (1.43; 1.69) o0.0001 0.41551
Gender 0.42 0.86668 (0.28; 0.63) 0.0001 0.88001
Pr12m 1.73 0.55057 (1.19; 2.51) 0.0038 0.61121
Pr12m
2 0.98 0.02110 (0.93; 1.03) 0.0005 0.04077
Gender * Pr12m 1.66 0.50685 (1.00; 2.75) 0.0490 0.48605
Gender * Pr12m
2 0.93 0.07623 (0.85; 1.00) 0.0520 0.06115
Abbreviations: CI, confidence interval; HR, hazard ratio; ROC, receiver–operator
characteristic.
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Figure 1 | Evolution of the risk to return in dialysis according
to the 10 Kidney Transplant Failure Score (KTFS) categories.
The hazard ratios according to the 10 KTFS categories are defined
by quantiles. The reference group is the lower KTFS interval with
hazard ratio¼ 1 (horizontal line). The vertical lines represent the
95% confidence intervals of each hazard ratio (n¼ 2169; 871
patients excluded from the computation of the KTFS owing to the
missing values for certain parameters).
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The KTFS decision threshold was calculated at 4.17, which
corresponds to the maximum value of sensitivity (0.72) and
specificity (0.71). Two grades were thus defined. Grade I was
the group with the lower risk of graft failure (KTFS p4.17)
and grade II was the group with the higher risk (KTFS
44.17). The graft survival curves are presented in Figure 4a.
One can see that at 8 years, the graft failure rate was 7.0% for
grade I versus 29.8% for grade II (Po0.0001). In all, 65% of
patients were classified as grade I and 35% as grade II. A total
of 31% of patients in grade I had kidneys from deceased
donors who met the expanded criteria donors, whereas the
percentage was 51.8% for patients in grade II (Po0.0001).
This difference in distribution of the expanded criteria donor
transplants did not explain the predictive capacities of the
KTFS, because graft survival between the expanded criteria
donor and non-expanded criteria donor transplants was not
significant (P¼ 0.2520).
Validation in the independent test set
The capacity of the KTFS to predict 8-year graft failure was
also analyzed for the test set (317 independent patients from
four different centers). Figure 3b shows the ROC curves and
also that the KTFS was still the predictor with the best
accuracy (AUC¼ 0.78, CI95%¼ (0.71, 0.86)). It outperformed
the Cr (AUC¼ 0.67, CI95%¼ (0.58, 0.78)), the eGFR
(AUC¼ 0.67, CI95%¼ (0.56, 0.78)), and the DCr between
6 and 12 months post-transplant (AUC¼ 0.61, CI95%¼
(0.53, 0.79)). The prognostic capacity of the KTFS was thus
still higher than the 1-year Cr (P¼ 0.0050), the 1-year eGFR
(P¼ 0.0083), and the DCr (P¼ 0.0300).
Figure 4b also shows that the threshold of 4.17
discriminated the two groups according to graft survival.
The graft failure rate of patients in grade I was 8.2% at 8 years
versus 25.3% in grade II (Po0.0001). In this test set, 74.5%
of patients were classified as grade I and 25.5% as grade II.
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Figure 2 |Distribution of the Kidney Transplant Failure Score
(KTFS) calculated in the training population (n¼ 2169).
Histogram of the KTFS calculated in the training population,
representing the distribution of the composite end point
(n¼ 2169).
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Figure 3 |8-Year predictive properties of the Kidney
Transplant Failure Score (KTFS). (a) Receiver–operator
characteristic (ROC) curves for 8-year predictions to evaluate the
prognostic capacity of the different markers. The KTFS (black line,
AUC¼ 0.78) is the most predictive marker. The usual surrogate
markers, 1-year Cr (red line, AUC¼ 0.73) and 1-year estimated
graft filtration rate (eGFR; green line, AUC¼ 0.70), show lower
predictive capacities. The evolution of creatinine (Cr) between
6 and 12 months is the worst marker (blue lines, AUC¼ 0.60). The
area under the ROC curve of the KTFS is higher than those of the
others (Po0.0001, one-tailed test by bootstrap resampling).
(b) ROC curves for 8-year prediction applied to the independent
testing set. The results are similar to those obtained in the training
set. The KTFS (black line, AUC¼ 0.78) is the most predictive
marker. The usual surrogate markers, 1-year Cr (red line,
AUC¼ 0.67) and 1-year eGFR (green line, AUC¼ 0.67), show lower
predictive capacities. The evolution of Cr between 6 and 12
months is the worst marker (blue line, AUC¼ 0.61). The area under
the ROC curve of the KTFS is higher than those of the others
(Po0.05, one-tailed test by bootstrap resampling).
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DISCUSSION
The early prediction of long-term outcome in kidney
transplantation has become a major issue, not only for
guiding clinical management but also for shortening the
survey period. In this paper, we present a non-invasive
composite clinical tool, called the KTFS, as a surrogate for
long-term graft outcome. Although our paper describes the
KTFS in a given clinical context, the method has the potential
to be substantially improved and adapted to other types of
transplantation or with other cohorts (different variables or
patients).
The KTFS was calculated from 2169 kidney recipients.
It combines risk factors of graft loss, including Cr values (at
3 and 12 months), proteinuria value (at 12 months),
recipient age and gender, number of previous transplanta-
tions, donor Cr value, and rejection episodes. All these
parameters were collected within the first post-transplant
year. The KTFS has been shown to have properties that are
useful for the prediction of graft failure up to the eighth post-
transplant year. A patient with a KTFS o4.17 is predicted to
have a functioning graft on the eighth anniversary of
transplantation, with a 93% chance of accuracy. However, a
patient with a KTFS44 has a 29.8% risk of renal failure. We
also compared the prognostic capacities of the KTFS with
various other markers of kidney graft function, namely 1-year
Cr, 1-year eGFR, as well as the change in Cr level between 6
and 12 months. The capacity of the KTFS to predict graft
failure was significantly better. It comes as no surprise that
the KTFS works better than the 1-year Cr, eGFR, or Cr
change between 6 and 12 months, because these variables are
included in the KTFS. However, this is the first time that a
composite approach has been proposed and evaluated
properly.
In contrast to the study by Kaplan et al.,21 we showed that
Cr and its eGFR are acceptable predictors of graft survival.
This difference is probably because of the statistical
modelling, as Kaplan et al.21 used conventional ROC curves.
In contrast, we have used in the present paper an ROC
method adapted to survival data.30
The robustness of the results obtained from the training
set was consolidated by including a test set of 317 patients,
which was completely independent. This validation analysis
yielded similar results even though the patients differed for
several parameters included in the KTFS, such as younger age
of recipient and donor, higher percentage of male donors,
and less number of re-transplanted patients.
The analysis has been also developed in accordance with
the intended clinical application, and the KTFS can be used
with a threshold value for medical decision-making. The
KTFS could thus be adapted with the aim of providing a
simple and useful tool for physicians to predict, at 1 year, the
future outcome of the patient.
One limitation of the KTFS is that it is restricted to
patients who have maintained their graft function for at least
1 year post-transplantation. For this reason, patients who had
lost their kidney transplants during the first year were
excluded from this study (22 deaths with a functioning graft
and 216 transplant failures). However, when we analyzed the
causes of graft failure during the first year, we identified
specific events including 84 vascular thromboses, 45
irreversible rejection episodes, 15 early relapses of initial
disease, 16 never-functioning kidneys, 10 severe surgical
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Figure 4 |Graft survival functions according to the Kidney
Transplant Failure Score (KTFS) grades (threshold calculated at
4.17 by maximizing both the sensitivity and the specificity).
(a) Estimation of transplant survival during the first 8 years post-
transplantation and according to the two grades defined at 1-year
post-transplantation. The dark line indicates the low-risk
subgroup (grade I), with a 93% probability of having a functional
kidney at 8 years post-transplantation. The survival of the grade II
subgroup (red line) is lower, with an 8-year probability of survival
estimated at 70.2%. The difference between the two curves is
highly significant (log-rank test, Po0.00001). (b) These are the
same survival curves, but estimated from the test set. The dark
line represents the low-risk subgroup (grade I), with a 91.8%
probability of having a functional kidney at 8 years post-
transplantation. The survival of the grade II subgroup (red line) is
lower with an 8-year probability of survival estimated at 75.8%.
The difference between the two curves is still highly significant
(log-rank test, Po0.00001).
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complications, 23 severe dysfunctions, and 43 failures of
unknown cause. These early graft failures are clearly different
from those associated with long-term survival. Although the
aim of the KTFS described here was to predict long-term
graft failure as early as possible, it would also be feasible to
test a score based on parameters collected at 3 or 6 months
post-transplant or even only on pre-transplant parameters.
In summary, we have built a new, simple, and non-
invasive clinical score to more accurately predict the long-
term graft outcome. We believe that this score could be used
as a new end point for clinical trials or as a decision tool in
the clinical management of kidney transplant recipients. But,
even if the KTFS was already validated on an independent
cohort, it would also be useful to see some further validations
and improvements in different cohorts throughout the world.
MATERIALS AND METHODS
Study sample and Donne´es Informatise´es et VAlide´es en
Transplantation (DIVAT) data bank
We based our analysis on data regarding kidney transplant recipients
prospectively collected between January 1996 and November 2007
and computerized in the DIVAT data bank. The biological and
clinical data within DIVAT are prospectively recorded according to a
common thesaurus at the participating centers (since 1996 for
Nantes and Paris Necker, since 1998 for Nancy, and since 2003 for
Toulouse and Montpellier). Yearly audits between all participating
centers showed o1% error in the collected data. Recorded
parameters included donor age, gender, and last donor Cr level
before kidney retrieval, as well as recipient age, weight, size, gender,
previous transplantations, cold ischemia time, delayed graft function
(defined by the time taken to attain a calculated clearance X10ml/
min), highest level of panel reactive antibodies on T cells, and HLA
A-B-DR incompatibilities.27 Post-transplant acute rejection episodes
are additionally collected in real time. The French law does not
authorize the storage of patient ethnicity. Finally, Cr and daily
proteinuria were also recorded at 3 and 6 months as well as annually.
The eGFR was calculated using the four-variable Modification of Diet
in Renal Disease formula.31 Only adult recipients of organs from
heart-beating deceased donors with a functional transplant on the first
anniversary of their transplantation were included in the study. With
regard to all these selection criteria, 2169 patients with all parameters
collected were included.
Independent test sample for external validation
An additional sample set of 317 independent kidney transplanta-
tions was used to validate the results obtained from the training
sample (DIVAT). For this test sample, the same data (double-
checked) from four other French transplantation centers (Caen,
Grenoble, Tours, and Strasbourg) were collected between April 1995
and January 2006.
Calculation of the KTFS
The KTFS is a score calculated to optimize the prediction of the time
between transplantation and graft failure (that is, return to dialysis).
Death is considered as a censored event. A multivariate Cox model29
was performed to initially integrate all significant risk factors
(Po0.15). The proportional hazard assumption was tested using
weighted residuals.32 As the objective was not to interpret the
different factors but to use them to construct a score, they were
included in the model using more flexible transformations
(polynomial and logarithmic functions, interactions between
variables) than those in classical survival analyses. However, if no
transformation was adequate to respect the log linearity, the
quantitative variables were categorized. These transformations or
cutoff estimations were performed to maximize the partial like-
lihood of the model. It must be noted that we did not use the usual
first error risk threshold of 0.05, a value adapted to prove a
correlation between the covariate and the survival with a very low
risk of error. In fact, our objective was to obtain the most complete
1-year composite end point. The resulting KTFS is equal to the sum
of the risk factor values, multiplied by the corresponding log hazard
ratios. Thus, as the graft failure risk increases, so does the KTFS. To
maximize the predictive capacity of this score, the weight (i.e., log
hazard ratios) of each parameter was corrected. The corrected
weights were obtained by maximizing the area under the ROC curve
(see the following paragraph).
Testing the predictive capacity of the KTFS
Diagnostic ROC curves. Usually, the ROC analysis assumes
that the disease status does not change over time, which is the case
when the diagnostic marker is measured at the same time as the
disease. However, this was not the case in our study, in which all
patients had a functioning kidney transplant, but this could fail
during the course of their follow-up, requiring adaptation of the
ROC curve for prognosis.
The adaptation of ROC. The time-dependent ROC method
was used here to analyze the capacity of a marker to predict a kidney
transplant failure. This method is based on the classical Kaplan and
Meier estimator33 converted using the Akritas approach.34 The
procedure takes into account the complexity of survival analysis
(censoring of the follow-up). Within this context, we addressed the
question of how well the KTFS, assessed at 1-year post-transplanta-
tion, could discriminate subjects who returned to dialysis before
their eighth transplantation anniversary from those who did not. We
chose the maximum prognostic time at 8 years, as only a few
patients were still being followed up after this time. We estimated
the decision threshold values of the KTFS by maximizing the
sensitivity and the specificity. For prognosis on the eighth
anniversary of transplantation, the sensitivity represents the
proportion of at-risk patients among those who have returned to
dialysis before this date. The specificity is the proportion of risk-free
patients among those who have not returned to dialysis before this
eighth anniversary.
Comparison with traditional markers
Finally, as the 1-year serum Cr and eGFR levels, and evolution of the
Cr between 6 months and 1-year post-transplantation (DCr) have
previously been proposed as markers of late graft loss,21,35 we
performed ROC analysis for these three markers so as to compare
their prediction capacities with that of the KTFS. These comparisons
were made using 1000 non-parametric bootstrap re-samples, in
which the differences between areas under the curve were calculated
at each iteration (one-tailed test).
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